MEDICAL : Allergan Names Board of Directors as Spinoff From SmithKline Nears

Allergan Inc. won’t be spun off from its parent SmithKline Beckman Corp. until this summer, but the Irvine eye- and skin-care product company has already named its board of directors.

SmithKline, a Philadelphia pharmaceutical giant, plans to distribute shares in its Allergan and Beckman Instruments Inc. subsidiaries to SmithKline stockholders before SmithKline merges most of its operations with the British firm Beecham PLC.

Fullerton-based Beckman created its board last year when SmithKline spun off 14% of Beckman’s stock to public investors. But Allergan remained a wholly owned subsidiary, so it had no board of directors until now.

Here is Allergan’s nine-member board:

Chairman Gavin S. Herbert Jr., who joined Allergan in 1955, seven years after his father founded the company. Herbert is also a director of SmithKline Beckman and Beckman Instruments.

William C. Shepherd, Allergan president since 1984. He joined the company in 1966.

Richard J. Flamson III, chairman of Security Pacific National Bank. His other directorships include Northrop Corp. and Coca-Cola Co.

William R. Grant, chairman of New York Life International Investment Inc. He is also a director of SmithKline Beckman and Irvine-based Fluor Corp., and he is a general partner of Amster & Co., a risk arbitrage firm.

Harry C. Groome III, president of SmithKline Bio-Science Laboratories, another SmithKline subsidiary. He joined SmithKline in 1963.

Kenneth N. Kermes, executive vice president of corporate finance for SmithKline. He is a director of Beckman Instruments.

Handel E. Evans, executive chairman of Walsh International, a supplier of information services to the health care industry. He is also a director of SmithKline.

Louis T. Rosso, president of Beckman Instruments.

Henry Wendt, chairman of SmithKline Beckman. He is also a member of the board of Atlantic Richfield Co.